Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System - Tabular View

Tracking Information
First Received Date ^ICMJE	November 3, 1999
Last Updated Date	March 4, 2008
Start Date ^ICMJE	April 1977
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00001158 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
Official Title ^ICMJE	Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
Brief Summary	The goal of the protocol is to define the normal humoral and cellular immune responses to antigens in volunteers and to define abnormalities of these immune responses in patients with immunodeficiency diseases or cancer. In vitro assays and in vivo skin tests and immunization with antigens will be utilized.
Detailed Description	The goal of the protocol is to define the normal humoral and cellular immune responses to antigens in volunteers and to define abnormalities of these immune responses in patients with immunodeficiency diseases or cancer. In vitro assays and in vivo skin tests and immunization with antigens will be utilized.
Study Phase
Study Type ^ICMJE	Observational
Study Design ^ICMJE
Condition ^ICMJE	Immunologic Deficiency Syndromes Neoplasms
Intervention ^ICMJE
Study Arms / Comparison Groups
Publications *	Nelson DL, Blaese RM, Strober W, Bruce R, Waldmann TA. Constrictive pericarditis, intestinal lymphangiectasia, and reversible immunologic deficiency. J Pediatr. 1975 Apr;86(4):548-54.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date	March 2000
Primary Completion Date
Eligibility Criteria ^ICMJE	Patients will be studied if a disorder of the immune system is suspected.
Gender	Both
Ages
Accepts Healthy Volunteers	Yes
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00001158
Responsible Party
Study ID Numbers ^ICMJE	770066, 77-C-0066
Study Sponsor ^ICMJE	National Cancer Institute (NCI)
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	National Institutes of Health Clinical Center (CC)
Verification Date	April 1999
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP